A new educational campaign aims to raise awareness of pulmonary arterial hypertension (PAH) symptoms, with the goal of accelerating diagnosis and improving treatment. The American Lung Association campaign has the support of Merck, which markets Winrevair (sotatercept), a medication approved this year in the U.S. and…
News
Cereno Scientific has secured loan financing to continue developing CS1, its lead therapeutic candidate for pulmonary arterial hypertension (PAH). The funds, totaling at least 250 million Swedish crowns (nearly $23 million), will help the company reach its milestones into 2026. This includes the U.S. Food and Drug Administration…
A Phase 2 clinical trial of TX45, Tectonic Therapeutic’s investigational therapy for pulmonary hypertension and heart failure with preserved ejection fraction (PH-HFpEF), has begun enrolling eligible patients. The Phase 2 study, called APEX (NCT06616974), is expected to recruit up to 180 adults with PH-HFpEF, ages…
Adding Uptravi (selexipag) to standard-of-care therapy within six months of starting treatment may reduce the risk of hospitalization and disease progression in people with pulmonary arterial hypertension (PAH), a study found. The study, “Early Addition of Selexipag to Double Therapy for Pulmonary Arterial Hypertension,” was…
Treatments that target the prostacyclin pathway hold promise as chronic thromboembolic pulmonary hypertension (CTEPH) treatment for patients who aren’t eligible for surgery, but more data is needed to verify the effectiveness of these medications in this type of pulmonary hypertension, according to the authors of a meta-analysis of…
Abnormalities in blood levels of various microRNAs (miRNAs) — small RNA molecules that regulate other genes in protein production — may contribute to the development and progression of chronic thromboembolic pulmonary…
The Pulmonary Hypertension Association (PHA) is fundraising and advocating with a campaign called “Let Your Light Shine” this November for this year’s pulmonary hypertension (PH) awareness month. “The efforts of PHA and the PH community are making a tremendous impact on the lives of those affected by PH,”…
Adults with severe pulmonary arterial hypertension (PAH) awaiting lung transplants can safely participate in pulmonary rehabilitation and maintain or improve exercise capacity, a study found. Pulmonary rehabilitation led to modest improvements in measures of aerobic training and in muscle training volumes with no major adverse events. However, participation in…
Children with pulmonary hypertension (PH), characterized by high blood pressure in the lungs that can make exercising difficult, are more likely to be active if physical activity is fun, allows them to be with friends, and puts them in a safe place where they feel included, a study has…
Researchers at Monash University in Australia will use newly granted funding to advance their work on a project that aims to create a novel disease-modifying treatment for pulmonary arterial hypertension (PAH). That funding came from Biocurate, a venture led by the University of Melbourne and Monash that aims…
An upcoming clinical trial will test whether empagliflozin, a drug widely approved to treat diabetes and heart failure, might be able to improve heart health in people with pulmonary arterial hypertension (PAH). The trial will be led by scientists at Cleveland Clinic, with study sites planned at two…
Long-term oxygen improves exercise capacity in people with pulmonary arterial hypertension (PAH) or chronic thromboembolic pulmonary hypertension (CTEPH), a study suggests. Twelve weeks of supplemental oxygen led to a significant and clinically relevant improvements in exercise capacity, as assessed with the six-minute walking distance test (6MWD), by 42…
